Prescient Therapeutics (ASX:PTX) has secured a significant regulatory milestone, with the European Medicines Agency granting Orphan Drug Designation to PTX-100 for the treatment of cutaneous T-cell lymphomas, including both mycosis fungoides and Sézary syndrome. …
Prescient secures EU orphan status for PTX-100 for cutaneous T-cell lymphomas
November 19, 2025 Australian Biotech
Latest Video
New Stories
-
Australian dementia experts push back on Cochrane Review, defending new treatments
April 20, 2026 - - Latest News -
Australia’s drug pricing dogma risks failing patients in the face of international realities
April 20, 2026 - - Latest News -
Free RSV vaccines roll out to protect senior Australians ahead of winter
April 20, 2026 - - Latest News -
Alterity strengthens board with seasoned biotech leader as it advances flagship therapy
April 19, 2026 - -
Immuron posts steady global gains as Travelan drives third quarter sales growth
April 19, 2026 - - Australian Biotech -
The 'Dispatched' Week in Review Podcast - 17 April
April 17, 2026 - - Podcast -
Mark Butler confirms new and expanded cancer medicine listings
April 17, 2026 - - Latest News